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Abstract 
Background:  Despite anti-VEGF therapy, some patients develop chronic diabetic macular edema. The objective of 
this study was to evaluate anatomic and visual outcomes of switching patients with chronic DME from intravitreal 
bevacizumab or ranibizumab to intravitreal aflibercept injection.
Methods: In this retrospective observational case series, 11 eyes with recalcitrant diabetic macular edema (DME) 
were evaluated 6 months prior to and 6 months following initial intravitreal aflibercept injection (IAI). Recalcitrant 
DME was defined as having a thickened retina (≥350 μm) on spectral domain optical coherence tomography (SD-
OCT) with persistent cystic changes (less than a 15% reduction in central retinal thickness) over 6 months prior to 
intravitreal aflibercept switch despite aggressive treatment for DME during this time.
Results: One hundred and forty-seven patients in total were treated with IAI during this time, and of these, 31 
patients were treated with IAI for DME. 18 eyes had less than 4 treatments within the 6 months prior to switch to IAI, 
6 patients had a central retinal thickness (CRT) on SD-OCT of less than 350 μm at time of switch to IAI, and 2 patients 
had a greater than 15% decline in CRT on SD-OCT over the 6 months prior to switch to IAI. A total of 11 patients were 
included in the study. Over the 6 months prior to switch, the mean change in central retinal thickness was +18.6% 
and over the 6 months following switch to aflibercept the mean change in central retinal thickness was −27.1%. 
Switching to a regimen of at least 3 intravitreal aflibercept injections over 6 months resulted in some anatomic 
improvement and improvement or stabilization of Snellen visual acuity in all eligible patients.
Conclusions: In patients with recalcitrant diabetic macular edema, switching to intravitreal aflibercept resulted in 
improved a 25% or more decrease in central retinal thickness in 81% (9/11) patients at 6-month follow-up. Sixty-three 
percent (7/11) had improvement in Snellen visual acuity after switching to intravitreal aflibercept injection, suggest-
ing some reversibility of functional damage.
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Background
Diabetic macular edema (DME) is the leading cause of 
central vision loss in people with diabetes and is char-
acterized by edema and thickening of the macula [1]. 
From the 1980’s until recently, macular laser photoco-
agulation, as evidenced by the Early Treatment Diabetic 
Retinopathy Study (ETDRS), remained the gold stand-
ard treatment for DME against which newer therapies 
were compared [2]. Recently, better understanding of the 
pathophysiology of DME highlighting the pivotal role 
of vascular endothelial growth factor (VEGF) and the 
introduction of anti-VEGF intravitreal agents has revolu-
tionized DME treatment [3]. In 2013, 90% of retinal spe-
cialists in the USA reported using anti-VEGF agents for 
initial management of DME [4].
Intravitreal ranibizumab (Lucentis; Genentech, San 
Francisco, California) became the first VEGF inhibitor 
FDA-approved for the treatment of DME in 2012 follow-
ing the RIDE and RISE trials, which showed significant 
superiority of both 0.3 and 0.5  mg ranibizumab groups 
over sham injection in improving visual acuity and 
decreasing central retinal thickness in patients with DME 
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[5]. Likewise, off-label use of intravitreal bevacizumab 
(Avastin; Genentech) has been shown to be effective in 
the treatment of DME through studies such as PACORES 
[6], BOLT [7], and a phase II trial put forth by the DRCR.
net [8].
In July 2014, the FDA approved intravitreal aflibercept 
(Eylea; Regeneron, Tarrytown, New York), a highly spe-
cific fusion protein with high VEGF-binding affinity, for 
the treatment of DME. This approval followed the VIVID 
and VISTA clinical trials, which showed superiority in 
anatomic and visual outcomes in patients treated with 
intravitreal aflibercept in comparison to laser treated 
controls. Patients in these studies required a 3-month 
washout period for patients previously treated with anti-
VEGF agents [9].
In March 2015, Protocol T of the Diabetic Retinopathy 
Clinical Research Network (DRCR.net) published results 
of a study comparing the relative efficacy of intravitreal 
bevacizumab, ranibizumab, and aflibercept in treatment 
of DME. They found that all three anti-VEGF treatments 
improved vision in center-involving DME, with the rela-
tive effect depending on baseline vision. In cases of mild 
vision loss (20/40 or better), there was no significant dif-
ference between the three treatment groups. However, 
in cases with poorer baseline visual acuity (20/50 or 
worse), aflibercept was significantly more effective than 
both ranibizumab and bevacizumab in improving vision. 
Although Protocol T provides data on the comparative 
effectiveness across the 3 anti-VEGF agents, this study 
was not designed to inform on the relative efficacy when 
switching agents, and excluded eyes that received an 
anti-VEGF injection within the preceding 12 months [4].
Since FDA approval of aflibercept for the treatment of 
DME and results from Protocol T, many ophthalmolo-
gists are switching patients from ranibizumab or beva-
cizumab to aflibercept, especially those with minimal 
or incomplete response to the former treatments. In the 
current study, we evaluated the outcome of switching to 
aflibercept (IAI) in patients with DME considered to be 
“recalcitrant” to therapy. Patients were deemed recal-
citrant if they had minimal decrease in central retinal 
thickness (CRT) on spectral domain optical coherence 
tomography (SD-OCT) despite aggressive treatment dur-
ing the prior 6 months.
Methods
A retrospective, observational case series was performed 
to study the outcome of switching to intravitreal afliber-
cept in eleven eyes with DME who were considered 
to be sub-optimal responders to standard of care and 
were considered to be “recalcitrant” to current therapy. 
The Institutional Review Board at Tufts Medical Center 
approved the study protocol for human subjects. The 
study was complaint with the Health Insurance Portabil-
ity and Accountability Act of 1996 and adhered to the 
tenets of the Declaration of Helsinki.
Intravitreal injection logs for all patients treated with 
intravitreal aflibercept 2.0  mg (0.05  mL) at two clinical 
sites of the Vitreoretinal Service at Tufts Medical Center 
Department between March 2014 and July 2015 were 
reviewed. Electronic medical records were then reviewed 
to identify possible participants that were treated with 
intravitreal aflibercept injection for DME.
Inclusion criteria included ability to provide writ-
ten informed consent, age 18 years or older, adequately 
clear media for SD-OCT imaging, and Snellen visual 
acuity of 20/40 to 20/300 in the study eye. Anatomic cri-
teria for inclusion required CRT ≥ 350 μm on SD-OCT 
and recalcitrant DME was defined as persistent cystic 
change with ≤15% decrease in CRT over the 6 months 
prior to IAI switch despite having at least 4 total treat-
ments for DME, with at least 3 of these treatments being 
intravitreal anti-VEGF injections (excluding IAI). Treat-
ments for DME prior to IAI switch included intravitreal 
bevacizumab (IVB) and ranibizumab (IVR), intravitreal 
triamcinolone acetonide (IVTA), sub-Tenon’s triamci-
nolone acetonide (STTA), dexamethasone intravitreal 
implant (Ozurdex; Allergan, Irvine, California), and 
laser photocoagulation. If both eyes of a patient met 
entry criteria, then the worse-seeing eye was included 
in the study. If patients were treated with previous cor-
ticosteroids, baseline intraocular pressure had to be 
21 mm Hg or less either with or without pressure reduc-
ing drops. Those patients who were previously treated 
with corticosteroids also had to have adequate clar-
ity of media to allow adequate SD-OCT image quality. 
Patients were excluded if they had previously received 
intravitreal aflibercept in the study eye or a history of 
systemic anti-VEGF therapy. Inclusion and exclusion 
criteria are outlined in Table 1.
Intravitreal injections were carried out using the same 
standard procedure in all patients. Dosing of intravitreal 
aflibercept was administered on a monthly as needed 
(PRN) regimen following the initial dose of aflibercept. 
The PRN treatment algorithm for DME entailed treat-
ment with intravitreal aflibercept and monthly monitor-
ing with SD-OCT. If at any point the central macula had 
no fluid at all, further aflibercept injections were with-
held and the patient was monitored on a monthly basis. If 
new or increase in fluid occurred from the previous visit 
secondary to worsening of diabetic macular edema, re-
treatment with intravitreal aflibercept was performed.
If the macula continued to have fluid after a minimum 
of 3 aflibercept injections and the macula achieved a 15% 
or more reduction in CRT compared to baseline on SD-
OCT, then treatment could be withheld. If the macula 
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continued to have fluid after a minimum of 3 aflibercept 
injections and the macula achieved <15% reduction in 
CRT compared to baseline of SD-OCT, aflibercept was 
continued or an alternative therapy was considered (cor-
ticosteroids or laser). If alternative therapy was utilized, 
the patient was not included in this analysis.
Patient charts were reviewed until 6  months after the 
first aflibercept injection. At each visit, best-corrected 
distance visual acuity was measured using a standard-
ized Snellen chart, a comprehensive eye examination was 
performed including intraocular pressure measurement 
via applanation, and OCT imaging was obtained using 
Spectralis OCT (Heidelberg Engineering, Carlsbad, Cali-
fornia, USA) or Cirrus HD-OCT (Carl Zeiss Meditech, 
Dublin, California, USA).
The occurrence of any severe postoperative complica-
tions, including infection, inflammation, retinal detach-
ment, thromboembolic events, or death within the 
first 6  months after the first aflibercept injection was 
recorded.
Results
The injection logs were reviewed for all patients receiv-
ing IAI between March 1, 2014 and July 1, 2015. One 
hundred and forty-seven patients in total were treated 
with IAI during this time, and of these, 31 patients 
were treated with IAI for DME. Twenty patients were 
excluded from the study for the following reasons: 18 
eyes had less than 4 treatments within the 6  months 
prior to switch to IAI, 6 patients had a CRT on SD-
OCT of less than 350 μm at time of switch to IAI, and 2 
patients had a greater than 15% decline in CRT on SD-
OCT over the 6 months prior to switch to IAI. A total of 
11 patients with DME meeting inclusion criteria for the 
study were evaluated. The mean patient age was 65 years 
old (range 47–83  years). There were 7 men (64%) and 
4 women (36%), and 5 (45%) right eyes and 6 (55%) 
left eyes included in the study. The self-reported mean 
hemoglobin A1c was 7.2 (range 6.1–10) and the mean 
duration of diabetes was 15 years (range 5–34 years) at 
the time of enrollment in the study. Baseline characteris-
tics are outlined in Table 2. 
Treatment characteristics
The average duration of treatment duration for DME 
prior to inclusion in the study was 32  months (range 
8–77  months). The mean total number of treatments 
given prior to inclusion in the study was 13 (range 
5–30) and included intravitreal bevacizumab, intravit-
real ranibizumab, intravitreal triamcinolone acetonide, 
sub-tenon triamcinolone acetonide, dexamethasone 
intravitreal implant, and focal laser. The anti-VEGF 
injections given prior to inclusion in the study included 
ranibizumab exclusively in 4 patients (36%), bevacizumab 
exclusively in 2 (18%) patients, and a combination of 
ranibizumab and bevacizumab in 5 (46%) patients. Other 
treatments included intravitreal triamcinolone acetonide 
(5 patients, 46%), sub-tenon triamcinolone acetonide (1 
patient, 9%), focal laser (8 patients, 73%), and dexametha-
sone intravitreal implant (1 patient, 9%).
The average number of treatments for DME adminis-
tered to the cohort during the 6 months before switch 
to IAI was 4.7 (range 4–6), with an average of 4.3 (range 
3–6) being anti-VEGF injections. Eight patients (73%) 
were treated with ranibizumab exclusively, 2 patients 
(18%) were treated with bevacizumab exclusively, and 1 
patient (9%) was treated with a combination of ranibi-
zumab and bevacizumab. Other treatments included 
intravitreal triamcinolone acetonide (1 patient, 9%) and 
focal laser (4 patients, 36%). No patients received panret-
inal photocoagulation during this time.
During the 6 months after switch to IAI, an average of 
4.7 (range 4–6) IAI were given. All patients had 6-month 
follow-up after switching to IAI and this visit was used 
for outcome analysis. Treatment characteristics are out-
lined in Table 3.
Anatomic outcomes
The average CRT as measured on SD-OCT at 6 months 
prior to switch to IAI was 428 μm (range 299–690). 
The mean change in CRT during the 6 months prior 
to switch to IAI was an 18.6% increase. The average 
CRT at time of switch to IAI was 487 μm (range 363–
685). At 6 months following switch to IAI, the average 
CRT was 326 μm (range 262–454). The mean change 
in CRT during the 6  months after switch to IAI was 
Table 1 Pre-defined inclusion and exclusion criteria
Inclusion criteria
 Able to provide informed consent
 Age 18 years or older
 Clear ocular media
 Baseline IOP of 21 mmHg or less with or without pressure-lowering 
drops in patients previously treated with corticosteroids
 Snellen visual acuity between 20/40 and 20/300
 CRT on SD-OCT ≥350 μm at the time of switch to IVE
 Minimum of 4 treatments for DME, with at least 3 being anti-VEGF intra-
vitreal injections (excluding IAI), administered within the 6 months 
prior to IAI switch
 <15% decrease in CRT during the 6 months prior to IAI switch (worsen-
ing)
 3 or more IAI within 6 months after switch
Exclusion criteria
 Previous IAI in the study eye
 History of systemic anti-VEGF use
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a 27.1% decrease. Anatomic and Snellen visual acuity 
outcomes before and after switch to IAI are outlined 
in Table 4.
At 6 months after switch to IAI, 9 of 11 patients (81%) 
had a 15% or more decrease in CRT, meeting the pri-
mary endpoint. At 6 months after switch to IAI, 9 of 11 
patients (81%) had a 25% or more decrease in CRT and 1 
of 11 patients (9%) had a 50% or more decrease in CRT. 
Eight of 11 patients (73%) had a CRT of less than 350 μm. 
Representative SD-OCT data before and after switch to 
intravitreal aflibercept is shown in Fig. 1.
Visual outcomes
Six months prior to switch to IAI, the Snellen visual 
acuity ranged from 20/25 to 20/100. Over the 6 months 
prior to switch to IAI, the Snellen visual acuity declined 
in 8 patients (73%), improved in 2 patients (18%), and 
remained unchanged in 1 patient (9%). At time of switch 
to IAI, the Snellen visual acuity ranged from 20/40 to 
20/200. Six months after switch to IAI, there was some 
improvement in Snellen visual acuity in 7 patients (63%) 
and remained stable in 4 patients (36%). No patients had 
decline in Snellen visual acuity after switch to IAI.
Table 2 Demographics and clinical characteristics of patients with DME switched to IAI
# Age (years) Gender Study eye HBAlc (%), self-reported Duration DM (years), self-reported
1 78 M OD 7 20
2 64 M OD 6.1 5
3 47 M OS 8 15
4 47 M OS 7.6 34
5 65 F OS 6.4 5
6 62 M OD 10 7
7 83 M OS 6.5 20
8 64 F OS 6.5 30
9 80 F OD 7 15
10 54 F OD 8 6
11 66 M OS 6.6 13
Mean = 65 Mean = 7.2 Mean = 15
Table 3 Treatment characteristics prior to  inclusion in  the study, 6  months prior to  IAI switch, and  6  months after  IAI 
switch




Total # treatment Type of treatment Total # treatment Type of treatment Total # IAI
l 60 26 6 IVB, 16 IVR, 2 IVTA, 1 
STTA, 1 laser
5 5 IVR 4
2 18 10 4 IVB, 4 IVR, 1 IVTA, 1 laser 5 3 IVR, 1 IVTA, 1 laser 6
3 8 5 2 IVB, 3 IVR 4 1 IVB, 3 IVR 5
4 35 30 29 IVB, 1 laser 5 4 IVB, 1 laser 4
5 43 16 7 IVB, 8 IVR, 1 IVTA 5 5 IVR 6
6 9 5 4 IVR, 1 laser 5 4 IVR, 1 laser 4
7 19 16 16 IVR 5 5 IVR 5
B 36 18 6 IVB, 7 IVR, 2 IVTA, 1 
dexamethasone intra-
vitreal implant, 2 laser
6 6 IVR 4
9 10 6 4 IVR, 1 IVTA, 1 laser 4 3 IVR, 1 laser 5
10 77 7 5 IVR, 2 laser 4 4 IVR 4
11 33 6 5 IVB, 1 laser 4 4 IVB 5
Mean = 32 Mean = 13 Mean # anti-VEGF = 11.5 Mean = 4.7 Mean # anti-VEGF = 4.3 Mean = 4.7
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Adverse events
After inclusion in the study, 52 anti-VEGF injections 
were given prior to switch, and 52 aflibercept injec-
tions were given after the switch. No ocular adverse 
events, including endophthalmitis, uveitis, retinal tears 
or detachment, or elevated intraocular pressure necessi-
tating treatment were observed. There were no systemic 
adverse events such as thromboembolic phenomena 
Table 4 Anatomic and Snellen visual acuity outcomes 6 months prior to IAI switch, at time of  IAI switch, and 6 months 
after IAI switch
# 6 months prior to IVE switch Time of IVE switch 6 months after IVE switch




CRT (μ) Snellen visual 
acuity




1 299 +9.7 20/40 398 20/50 284 −23.1 20/40
2 490 +1.0 20/50 574 20/200 267 −44.3 20/70
3 496 −10.0 20/30 463 20/40 417 −5.7 20/25
4 313 +98.1 20/25 580 20/200 454 −34.4 20/200
5 460 +6.5 20/70 459 20/50 285 −34.5 20/50
6 384 +2.2 20/80 363 20/40 341 −5.7 20/40
7 383 +24.2 20/100 469 20/100 263 −40.0 20/50
8 690 +18.6 20/50 685 20/200 423 −13.2 20/200
9 353 +13.7 20/70 496 20/100 262 −41.9 20/70
10 347 +50.5 20/25 444 20/40 283 −36.4 20/25
11 498 −9.8 20/50 428 20/70 312 −18.6 20/40
Mean = 428 Mean = +18.6% Mean = 487 Mean = 326 Mean = −27.1%
Fig. 1 SD-OCT of patient 2, 9, and 10 at 6 months prior to IAI switch, at the time of IAI switch, and 6 months after IAI switch
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(myocardial infarction, transient ischemic attack, or cer-
ebrovascular accident) during the study.
Discussion
Inflammatory changes in the retinal environment are 
involved in the pathogenesis of DME, including vascular 
leakage, leukostasis, ischemia, and release of pro-inflam-
matory mediators such as VEGF, interleukins 6 and 8, 
and TNF-alpha [10]. The retinal microenvironment in 
early DME may be characterized by acute inflammation 
and vascular dysfunction, whereas anatomic changes and 
neurotoxic effects from chronic edema may characterize 
long-standing DME. These unique characteristics found 
in chronic DME may alter response to various treatments 
[10, 11].
In clinical practice, some patients have chronic fluid, 
despite aggressive treatment with intravitreal injections 
of bevacizumab or ranibizumab. It is important to know if 
there is benefit to switching incomplete or non-responders 
to an alternative anti-VEGF agent, rather than continuing 
ranibizumab or bevacizumab injections, switching to cor-
ticosteroids, or combining anti-VEGF and corticosteroid 
treatment. The current study used stringent criteria iden-
tify patients with recalcitrant DME to evaluate if switching 
to IAI would be of benefit. In this small study, switching 
to IAI resulted in some anatomic improvement in all eligi-
ble patients, and 81% of patients met the pre-specified pri-
mary endpoint of 15% or greater decrease in CRT.
Our results are consistent with two previously reported 
cases series. Wood, Karth, Moshfeghi, and Leng evalu-
ated short-term outcomes of switching to IAI in 14 eyes 
with persistent fluid from DME despite at least 3 monthly 
ranibizumab or bevacizumab. There was no minimum 
central retinal thickness requirement for inclusion and 
follow-up occurred after a single IAI. At 1 month after 
injection, 79% of patients had anatomic improvement on 
SD-OCT [12].
Rahimy et al. evaluated 50 eyes treated with at least 4 
consecutive injections with ranibizumab or bevacizumab 
prior IAI switch, and two or more IAI after switch. 
Included patients had minimum central retinal thick-
ness of 300 μm and follow-up occurred at month 2 or 3 
after switch to IAI. At most recent follow-up, 56% had 
anatomic improvement on SD-OCT, while 24% had com-
plete resolution of fluid [13].
The greater response to aflibercept in patients with 
chronic DME recalcitrant to treatment with bevaci-
zumab and ranibizumab may be due to a number of fac-
tors, and may help explain the results seen in Protocol T. 
Aflibercept has been shown to have significantly higher 
binding affinity to VEGF-A compared to ranibizumab 
and bevacizumab. Also, aflibercept binds to VEGF-B and 
placental growth factor (PlGF), unlike ranibizumab and 
bevacizumab [9]. These characteristics may contribute to 
aflibercept’s superior effects on vascular permeability and 
retinal neovascularization, and may make it more suit-
able to treating patients with a high VEGF load, such as 
in chronic DME.
It is unclear both from inconsistencies in the published 
literature and clinically as to what parameters should be 
used to define recalcitrant DME (visual acuity response, 
anatomic response, number of treatments, et cetera). The 
current study used pre-defined and very stringent crite-
ria for classifying patients as having recalcitrant DME, 
and included visual acuity, central retinal thickness, and 
treatment parameters. Recalcitrant patients were identi-
fied as those with substantially thickened retinas (>/350 
μm CRT) with minimal improvement in CRT (<15% 
across 6 months prior to switch) despite aggressive ther-
apy with at least four treatments for DME (3 of which 
were VEGFs other than aflibercept). These eyes were not 
improving anatomically prior to switch despite frequent 
anti-VEGF therapy. Switching to a pre-defined minimal 
use of aflibercept resulted in some anatomic improve-
ment in all eligible patients. All patients were followed 
for at least 6 months, with the majority of patients gained 
some visual acuity after switching to aflibercept, suggest-
ing some reversibility of functional damage.
The major limitations of this study include the retro-
spective design and the relatively small number of partic-
ipants, precluding the ability to apply statistical analyses. 
Further studies are needed on a larger scale but this small, 
retrospective study suggests that switching to aflibercept 
can be beneficial for recalcitrant DME patients as defined 
in this study.
Conclusions
In conclusion, in patients with recalcitrant DME, defined 
as having thickened retinas (≥350 μm) with minimal 
decrease in CRT (<15% over 6  months prior to switch) 
despite aggressive treatment (at least 4 treatments over 
6  months prior to switch, 3 being anti-VEGFs), switch-
ing to intravitreal aflibercept may result in improved ana-
tomic and visual outcomes at 6-month follow-up.
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